Di-O-benzoyl-3',5' O-acetyl-2' β-xylofurannosyl-9 adenine | 83373-05-1

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: Di-O-benzoyl-3',5' O-acetyl-2' β-xylofurannosyl-9 adenine
• 英文别名: [(2R,3S,4R,5R)-4-acetyloxy-5-(6-aminopurin-9-yl)-3-benzoyloxyoxolan-2-yl]methyl benzoate
• CAS: 83373-05-1
• 化学式: C₂₆H₂₃N₅O₇
• 分子量: 517.498
• InChiKey: FQVCSCHSSVDBKM-LOCCHRAXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  38
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  158
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  Di-O-benzoyl-3',5' O-acetyl-2' β-xylofurannosyl-9 adenine 在 吡啶 、 咪唑 、 4-二甲氨基吡啶 、 四丁基氟化铵 、 sodium methylate 、 一水合肼 、 溶剂黄146 作用下， 以 四氢呋喃 、 吡啶 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 71.5h， 生成 N,O-Dibenzoyl-6,3' O-monomethoxytrityl-5' β-D-xylofurannosyl-9 adenine
  参考文献：
  名称：

  Gosselin, Gilles; Imbach, Jean-Louis, Journal of Heterocyclic Chemistry, 1982, vol. 19, p. 597 - 602

  摘要：

  DOI：
• 作为产物：
  描述：

  Di-O-benzoyl-3,5 di-O-acetyl-1,2 α-D-xylofurannose 生成 Di-O-benzoyl-3',5' O-acetyl-2' β-xylofurannosyl-9 adenine
  参考文献：
  名称：

  ROBINS, MORRIS J.;MADEJ, DANUTA;HANSSKE, FRITZ;WILSON, JOHN S.;GOSSELIN, +, CAN. J. CHEM., 66,(1988) N 5, 1258-1262

  摘要：

  DOI：

文献信息

• Systematic synthesis and biological evaluation of .alpha.- and .beta.-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogs
  作者：Gilles Gosselin、Marie Christine Bergogne、Jean De Rudder、Erik De Clercq、Jean Louis Imbach

  DOI：10.1021/jm00152a007

  日期：1986.2

  anomers were obtained by a multistep synthesis with use of 2-amino- or 2-mercapto-alpha-D-xylofuran[1',2':4,5]-2-oxazoline as starting material. The xylofuranosyl nucleosides were tested for their activity against a variety of RNA and DNA viruses and for inhibition of cell growth and macromolecule synthesis. Three compounds, 9-(beta-D-xylofuranosyl)adenine, 9-(beta-D-xylofuranosyl)guanine, and 1-(

  天然存在的核苷的α-和β-D-木呋喃糖基类似物，以及其他D-木呋喃糖基衍生物，已成为其生物学（即抗病毒抗代谢和抑制细胞生长）特性的系统合成和研究对象。通过将嘌呤和嘧啶糖苷配基与过酰化的1-O-乙酰基-α-D-木呋喃糖基糖基化，然后除去保护基团来制备β端基异构体。通过使用2-氨基或2-巯基-α-D-木呋喃[1'，2'：4,5] -2-恶唑啉为起始原料的多步合成法获得α-端基异构体。测试了木呋喃糖基核苷对多种RNA和DNA病毒的活性以及对细胞生长和大分子合成的抑制作用。9-（β-D-木呋喃糖基）腺嘌呤三种化合物
• Methods of treating hepatitis delta virus infection with beta-l-2'-deoxy-nucleosides
  申请人：——

  公开号：US20020035085A1

  公开（公告）日：2002-03-21

  A method and composition for treating a host infected with hepatitis D comprising administering an effective hepatitis D treatment amount of a described 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof.

  一种治疗感染乙型肝炎的宿主的方法和组合物，包括给予所述2'-脱氧-β-L-赤霉糖核苷或其药用可接受的盐或前药的有效乙型肝炎治疗剂量。
• [EN] beta -L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B<br/>[FR] beta -L-2'-DESOXY-NUCLEOSIDES POUR LE TRAITEMENT DE L'HEPATITE B
  申请人：NORIVIO PHARMACEUTICALS LTD

  公开号：WO2000009531A2

  公开（公告）日：2000-02-24

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2'-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2'-deoxy-β-L-erythro-pentofuranonucleoside has formula (I) wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2'-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2'-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予有效量的抗HBV生物活性2'-脱氧-β-L-erythro-戊糖核苷或其药学上可接受的盐或前药，其中2'-脱氧-β-L-erythro-戊糖核苷具有式(I)，其中R选自H、直链、支链或环烷基、CO-烷基、CO-芳基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单磷酸、二磷酸或三磷酸或磷酸衍生物；而基团是一种可以选择性地被取代的嘌呤或嘧啶碱基。2'-脱氧-β-L-erythro-戊糖核苷或其药学上可接受的盐或前药可以单独给予或与另一种2'-脱氧-β-L-erythro-戊糖核苷或另一种抗乙型肝炎药物联合给予。
• Beta-L-2'-deoxy-nucleosides for the treatment of hepatitis B
  申请人：Centre National da la Reserche Scientifique

  公开号：US20030220290A1

  公开（公告）日：2003-11-27

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: 1 wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予一种抗HBV生物活性2'-脱氧-β-L-核糖呋喃核苷或其药学上可接受的盐或前药的有效量，其中2'-脱氧-β-L-核糖呋喃核苷的化学式为：1，其中R选自H、直链、支链或环烷基、CO-烷基、CO-芳基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单、二或三磷酸盐或磷酸衍生物；BASE是嘌呤或嘧啶碱基，可以选择性地被取代。2'-脱氧-β-L-核糖呋喃核苷或其药学上可接受的盐或前药可以单独使用或与另一种2'-脱氧-β-L-核糖呋喃核苷或另一种抗乙型肝炎药物联合使用。
• Beta-L-2'deoxy-nucleosides for the treatment of hepatitis B
  申请人：——

  公开号：US20030225028A1

  公开（公告）日：2003-12-04

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: 1 wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予一种抗HBV生物活性的2'-去氧-&bgr;-L-核糖核苷或其药用盐或前药的有效量，其中2'-去氧-&bgr;-L-核糖核苷具有以下公式：1其中R选自H、直链、支链或环烷基、CO-烷基、CO-芳基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单、二或三磷酸盐或磷酸衍生物；BASE是一种可以选择性地取代的嘌呤或嘧啶碱基。2'-去氧-&bgr;-L-核糖核苷或其药用盐或前药可以单独或与另一种2'-去氧-&bgr;-L-核糖核苷或其他抗乙型肝炎药物联合使用。